Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 9/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 9/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 9/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 9/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 9/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 10/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411656 | 0.95 | PSEN1 (0.91) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8818024 | 0.83 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9260430 | 0.83 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9266733 | 0.82 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8819368 | 0.81 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3316422 | 0.81 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4456548 | 0.79 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8818205 | 0.78 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4107745 | 0.77 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3038471 | 0.77 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.